Drug news
European Commission approves Taltz (ixekizumab) to treat moderate-to-severe plaque psoriasis in adults- Eli Lilly
Eli Lilly has received approval from The European Commission for Taltz (ixekizumab) to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.
Taltz is the second IL-17-targeting drug to reach the market after Cosentyx (secukinumab) from Novartis. Cosentyx has started well in particularly in Germany. Lilly is expecting to start rolling out Taltz in EU countries from this summer and through to the end of 2018. Taltz was approved by the FDA in March 2016.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.